Chat
CYP2C8 and CYP2C9
Copy Utility
Assess genetic risk of abnormal drug metabolism for CYP2C8 and/or CYP2C9 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2C8 and/or CYP2C9.
Polymerase Chain Reaction/Fluorescence Monitoring
Varies
5-10 days
Whole Blood: Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Saliva: Collection Device by DNA Genotek (OCD-100, ARUP Supply #49295) available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787.
Transport 3 mL whole blood. (Min: 1 mL) OR Transport the Saliva Collection Device.
Whole Blood: Refrigerated.
Saliva: Room temperature.
Plasma or serum. Specimens collected in sodium heparin or lithium heparin.
Whole Blood: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Saliva: Ambient: 2 weeks; Refrigerated: Unacceptable; Frozen: Unacceptable
By report
Background Information for CYP2C8 and CYP2C9:
Characteristics: The cytochrome P450 (CYP) isozymes 2C8 and 2C9 are involved in the metabolism of many drugs. Variants in the genes that code for CYP2C8 and CYP2C9 may influence pharmacokinetics of substrates, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions.
Inheritance: Autosomal codominant.
Cause: CYP2C8 and CYP2C9 gene variants affect enzyme expression or activity.
Variants Tested: See the "Additional Technical Information" document.
Clinical Sensitivity: Drug-dependent.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: Only the targeted CYP2C8 and CYP2C9 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Publically available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2C8 or CYP2C9 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.
Please note the information contained in this report does not contain medication recommendations, and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Whole blood is the preferred specimen. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting.
Hotline History
81227; 81479
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3001502 | 2C8/2C9 Specimen | 31208-2 |
| 3001503 | CYP2C8 Genotype | 78972-7 |
| 3001504 | CYP2C9 Genotype | 46724-1 |
| 3001505 | 2C8/2C9 Interpretation | 50398-7 |
- 2C8
- 2C9
- Coumadin
- CYP2C8
- CYP2C9
- Cytochrome P450 2C8
- Cytochrome P450 2C9 Genotype
- glibenclamide
- gliclazide
- glimepiride
- mayzent
- phenytoin
- siponimod
- sulfonylureas
- tolbutamide
- warfarin
Feedback
